Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a
  Single, Sequence-Guided Deep Generative Framework
  The COVID-19 pandemic has highlighted the urgency for developing more
efficient molecular discovery pathways. As exhaustive exploration of the vast
chemical space is infeasible, discovering novel inhibitor molecules for
emerging drug-target proteins is challenging, particularly for targets with
unknown structure or ligands. We demonstrate the broad utility of a single deep
generative framework toward discovering novel drug-like inhibitor molecules
against two distinct SARS-CoV-2 targets -- the main protease (Mpro) and the
receptor binding domain (RBD) of the spike protein. To perform target-aware
design, the framework employs a target sequence-conditioned sampling of novel
molecules from a generative model. Micromolar-level in vitro inhibition was
observed for two candidates (out of four synthesized) for each target. The most
potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with
broad-spectrum activity against several SARS-CoV-2 variants in live virus
neutralization assays. These results show that a broadly deployable machine
intelligence framework can accelerate hit discovery across different emerging
drug-targets.
